Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Disparities in HIV diagnosis rates were observed between Black and White individuals in the US from 2017 to 2021.

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

New Study Identifies Key Protein's Role in Psoriasis Jan. 31, 2025 — In a new study, researchers have determined that a protein called NF-kB c-Rel can intensify the symptoms of psoriasis when ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

For decades, external actors, such as donors, funders, and implementing partners, have shaped Africa's HIV response. Although this strategy has saved millions of lives, it entrenched dependency, ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV infection and set a date of June 19 to decide on its approval, Gilead ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Bush-era program for combatting HIV and AIDS around the globe. That program has now been largely dismantled by the Trump administration. A Gilead spokesperson declined to comment on what cuts to ...

Kenya has the seventh-largest number of people living with HIV in the world, at around 1.4 million, according to World Health Organization data. The President's Emergency Plan for AIDS Relief ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...